The HIV Care Cascade from HIV diagnosis to viral suppression in sub-Saharan Africa: a systematic review and meta-regression analysis protocol. by Güler, Aysel et al.
PROTOCOL Open Access
The HIV Care Cascade from HIV diagnosis
to viral suppression in sub-Saharan Africa:
a systematic review and meta-regression
analysis protocol
Aysel Gueler1, Fiona Vanobberghen2, Brian Rice3, Matthias Egger1,4 and Catrina Mugglin1*
Abstract
Background: In 2014, UNAIDS announced the 90-90-90 treatment targets to curb the HIV epidemic by 2020: 90%
of people living with HIV know their HIV status, 90% of people who know their HIV status access treatment and
90% of people on treatment have suppressed viral loads. Monitoring and evaluation are needed to track linkage
and retention throughout the continuum of care. We propose a systematic review and meta-regression to identify
the different methodological approaches used to define the steps in the HIV care cascade in sub-Saharan Africa
(SSA), where most people with HIV live, and to assess the proportion of participants retained at each step.
Methods: We will include cohort and cross-sectional studies published between 2004 and 2016 that report on the
HIV care cascade among adults in SSA. The PubMed, Embase and CINAHL databases will be searched. Two reviewers
will independently screen titles and abstracts, assess the full texts for eligibility and extract data. Disagreements will be
resolved by consensus or consultation with a third reviewer. We will assess the number and proportion of individuals
retained in the HIV care cascade from HIV diagnosis to linkage to care, engagement in pre-ART care, initiation of ART,
retention on ART, and viral suppression. The data will be analysed using random effects meta-regression analysis.
Publication bias will be assessed by funnel plots.
Discussion: This review will contribute to a better understanding of the HIV care cascade in SSA. It will help programs
identify gaps and approaches to improve care and treatment for people living with HIV and reduce HIV transmission.
Systematic review registration: PROSPERO CRD42017055863
Keywords: HIV, HIV care cascade, Antiretroviral therapy, HIV diagnosed, Linkage to care, Viral suppression, HIV care
continuum, Systematic review, Meta-analysis, Sub-Saharan Africa
Background
In 2014, UNAIDS proposed the 90-90-90 Fast-Track
treatment targets to curb the HIV/AIDS epidemic.
These targets stipulate that, by 2020, 90% of people liv-
ing with HIV worldwide should know their diagnosis,
90% of these people should be on antiretroviral therapy
(ART), and 90% of these persons (i.e., 73% of all people
living with HIV) should be virally suppressed [1–3].
The HIV care cascade, also known as the HIV care
continuum, outlines the sequential steps of HIV care
from initial diagnosis to the goal of viral suppression
[4, 5] (Fig. 1). To achieve universal access to HIV care and
treatment with viral suppression, each HIV-positive indi-
vidual must progress along this cascade. HIV testing ser-
vices [6, 7], earlier diagnosis [8, 9], linkage and retention
in care [10–12] and earlier ART initiation [13–16] are key
components to achieve the 90-90-90 goals [17].
The cascade can be used to evaluate HIV programme
performance and serve as a monitoring tool to identify
gaps and opportunities for specific interventions to
improve outcomes [18]. In sub-Saharan Africa (SSA) and
elsewhere, significant gaps remain [19–21], and retention
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along the HIV care cascade remains a major problem
[22–27]. However, studies analysing the HIV care cas-
cade use different methodologies and calculations to
construct the cascade. For each element in the cascade,
either measured or estimated, definitions vary and
methods are often not well described [5]. The use of
different measures, for example how retention in HIV
care is defined or the threshold for viral suppression, to
estimate the cascade stages may affect the results [28].
It is therefore difficult to compare published cascades
across regions and calendar periods.
Few studies have evaluated the methods used to define
the HIV care cascade in low- and middle-income coun-
tries, or in SSA [18]. A previous systematic review from
2014 looking at the whole cascade from HIV testing to
viral suppression failed to identify any eligible studies
from low-income countries [29]. A more recent review
evaluated the cascade based on national estimates but did
not include smaller in-depth studies [30]. In SSA, surveys
conducted between 2007 and 2011 found that 36% of
people in the region had never been tested for HIV [31],
and less than 50% of HIV-positive persons knew their
Fig. 1 HIV care cascade and assessment of ART eligibility (adapted from WHO guidelines [34]). ART, antiretroviral therapy; IDU, injection drug use;
LTP, loss to programme; MSM, men who have sex with men; PLHIV, people living with HIV; VL, viral load
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HIV status [20]. Focusing on SSA, we aim to perform a
systematic review and meta-regression analysis to assess
the different methodological approaches used to define the
steps in the HIV care cascade and to estimate the numbers
or proportion of people retained in each cascade step.
Methods
This systematic review protocol was written following
the Preferred Reporting Items for Systematic Review and
Meta-analysis Protocols (PRISMA-P) guidelines [32]. The
PRISMA-P checklist can be found as Additional file 1.
Aims
The first aim of this systematic review is to describe the
different concepts and methodologies used in the pub-
lished literature to define the steps in the HIV care cas-
cade in SSA. The second aim is to obtain comparable
measures of the number or proportion of people retained
in the different steps of the HIV care cascade, based on
the findings from the first aim.
Eligibility criteria
Study designs and setting
We will include cohort and cross-sectional studies with
data collected between January 2004 and March 2016 in
any country in SSA (Table 1). Studies that examine two
or more of the following cascade elements will be in-
cluded: the number or proportion of persons diagnosed
with HIV (first UNAIDS 90-90-90 treatment target), link-
age of HIV-positive persons to pre-ART care, retention in
pre-ART care, initiating ART, remaining on ART (second
UNAIDS 90-90-90 treatment target), and virological
suppression among persons on ART (third UNAIDS
90-90-90 treatment target).
Population
We will include studies of the general population living
with HIV. This will encompass male and female partici-
pants living with HIV-1 aged 15 years or older. We will
exclude studies of patients with specific co-morbidities
such as tuberculosis or opportunistic infections. Studies in
patients with HIV-2 will also be excluded. If the HIV type
is not specified, HIV-1 will be assumed. We will exclude
studies of prevention of mother-to-child transmission
(PMTCT) as the PMTCT care cascade differs substantially
from the general HIV care cascade [33, 34]. We will also
exclude intervention studies that examine the effectiveness
of measures to improve the HIV care continuum.
Outcomes
Primary outcomes The primary outcome is the concept,
methodology and definition used to identify a reported
stage of the cascade. We will describe these narratively
and classify studies into suitable groups.
Secondary outcomes The secondary outcomes include
the number or proportion of persons retained at each
cascade step (see also Fig. 1 and Additional file 2):
 HIV diagnosis (UNAIDS 90-90-90 treatment target)
 Linkage to pre-ART care
 Retention in pre-ART care
 On ART (UNAIDS 90-90-90 treatment target) with
Start of ART
Retention on ART
 Suppression of viral load (UNAIDS 90-90-90 treatment
target)
Information sources
Electronic databases
We have conducted a comprehensive literature search
with the help of two librarians with expertise in systematic
reviews. We restricted the search to articles published in
Table 1 Selection criteria
Criteria Variables
Inclusion criteria
HIV-positive people aged 15 years and older in
sub-Saharan Africa
Study period after 01 January 2004 (ART initiation
after 01 January 2004)
General population
Reporting on a cascade with two or more elements
(HIV diagnosed, linked to care, retained in care,
on ART, virally suppressed)
Observational studies: cohort or cross-sectional studies
Published in English, French or Spanish
Exclusion criteria
Publication type
Narrative reviews
Commentaries, editorials or letters
Conference abstracts
Study design
Randomized controlled trials
Qualitative studies
Case series
Simulations or modelling studies
Unclear study design
Study population
Populations outside sub-Saharan Africa
Children
Specific sub-populations (for example patients with
tuberculosis, or pregnant women)
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English, French and Spanish between January 2004 and
March 2016, since the scale-up of ART in SSA started
around 2004 [35, 36]. We performed the searches in
PubMed, Embase and CINAHL.
Search strategy
The Medical Subject Headings (MeSH terms) for HIV
and AIDS and key terms ‘cascade’, ‘continuum’, ‘linkage
to care’, ‘retention in care’ and ‘ART initiation’ were
cross-referenced with terms associated with 62 African
countries (Additional file 3 shows the detailed search
strategy). We will update the search prior to publication
to include any additional eligible papers published after
March 2016.
Study records
Data management
All records from our PubMed, Embase and CINAHL
searches will be combined, uploaded into the reference
management software Mendeley (version 1.15.3) and de-
duplicated. We will use Microsoft Excel (version 2016
for Windows, Microsoft Corp., Redmond, WA, USA) to
record outcomes of the selection process.
Selection of eligible studies
Two reviewers will independently screen studies in two
stages: title/abstract screening, followed by full text
screening. A checklist with the eligibility criteria will be
developed and pilot-tested on a random sample of 20
studies. Titles and abstracts will then be reviewed against
the eligibility criteria by AG and FV. We will obtain full
texts of all potentially eligible articles. Two reviewers will
independently apply inclusion criteria (Additional file 4) to
the full texts. At both screening steps, we will resolve dis-
agreements by consensus, if necessary through discussion
with a third reviewer (CM or ME). We will record all
discrepancies on Excel spreadsheets, with reasons for
inclusion or exclusion. The PRISMA study flow diagram
will reflect this process and detail the reasons for exclusion
of studies.
Data collection
We will develop a data extraction sheet to guide data
collection. This sheet will direct collection of the defin-
ition and methods for each step of the cascade, the re-
sults of estimations or calculations and sources of data.
The sheet will be pilot-tested by two reviewers (AG,
CM) on a random sample of 10 articles and revised as
needed. Two reviewers will independently read each art-
icle and extract the relevant data. Both sets of data will
be entered into Epidata version 3.1 (EpiData Association,
Denmark). Any discrepancies in the extracted data will
be resolved by consensus, in discussion with a third
reviewer (CM or ME) if necessary. We will contact study
authors to resolve any information that is not clear.
Data items
The data items for extraction will be informed by items
reported in the PRISMA statement [37–39]. We will
extract the following from included studies:
 Study characteristics (authors, year of publication,
study period, study population, study design, aim of
study, geographic location, duration of follow-up,
key finding);
 Study setting (location and type of facilities);
 Characteristics of study populations (sample size,
age, sex, marital status, weight, educational level,
employment status, enrolment period, inclusion and
exclusion criteria);
 Definitions and methods used to construct cascade;
 The number or proportion of persons diagnosed
with HIV (90-90-90 treatment target), linkage to
pre-ART care, retention in pre-ART care, on ART
(90-90-90 treatment target), virological suppression
(90-90-90 treatment target);
 Clinical and laboratory data (CD4 cell counts, viral
load, ART regimen, medical circumcision (only men),
TB status, other co-infections and comorbidities).
Data synthesis
The main characteristics of included studies will first be
narratively synthesized. Summary statistics will be used to
describe study characteristics, including means (standard
deviations) or medians (interquartile ranges), and frequen-
cies (percentages). For each step of the cascade, we will
calculate proportions with exact binomial 95% confidence
intervals (95% CI) and present these in forest plots. We
will calculate the between-study variance (tau-squared)
and p values from tests of between-study heterogeneity.
We expect substantial between-study heterogeneity, and
the focus of the subsequent analyses will therefore be on
the identification and exploration of sources of heterogen-
eity. We will explore associations between proportions at
each step and country, setting (e.g. urban, periurban, rural;
health care level, public or private setting) and study char-
acteristics (e.g. study size, sampling frame) using random
intercept logistic meta-regression (Binomial-Normal)
models. These models avoid the biases that arise when
Normal-Normal models (which model the within study
variability via normal approximations) are applied to logit
or arcsine-square root transformed proportions [40, 41].
Where appropriate, we will use the same models to cal-
culate combined estimates of proportions. All analyses
will be done in R version 3.2.3 (R Foundation, Vienna,
Austria).
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Dealing with missing data
If data are missing in key variables, we will contact the
study authors for clarification. A description of missing
data will be provided for each study, and we will discuss
the possible implications of missing data.
Risk of bias in included studies
Two pairs of reviewers (AG and CM) will assess in-
cluded studies using ROBINS-I, a tool for assessing risk
of bias in nonrandomized studies of interventions for
observational studies [42]. The tool will be adapted to
the context of this systematic review, and to cross-
sectional studies. ROBINS-I contains 34 questions from
seven different bias domains. For each study, relevant
domains of risk of bias will be graded as low, moderate,
serious, critical or no information for risk of bias [43].
Publication bias will be assessed by visually inspecting
funnel plot asymmetry and by including study size in the
logistic model. The quality assessment will be cross-
checked, and any disagreement will be resolved within
the review team.
Discussion
This systematic review and meta-analysis will contribute
to a better understanding of the different methodological
approaches used in sub-Saharan African countries to de-
fine the steps in the HIV care cascade and to estimate
the numbers or percentages of people retained at each
step of the cascade. We will identify gaps in the cascade
and areas for further research. Our results will be useful
for the design of strategies for improving the care and
treatment of people living with HIV and for reducing
HIV transmission. This review will thus be highly rele-
vant to inform health systems interventions and HIV
prevention and treatment strategies in sub-Saharan Africa,
and low- and middle-income countries in general.
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